About Microbix
Microbix is a company based in Mississauga (Canada) founded in 1988. Microbix offers products and services including Antigens, External Quality Controls, DxTM Viral Transport Medium, and Custom Vial Filling Services. Microbix operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Mississauga, Canada
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website microbix.com
- Social LinkedIn X Facebook YouTube
- Legal Name Microbix Biosystems Inc.
- Annual Revenue$13.35 M (USD)-26.81as on Sep 30, 2025
- Net Profit-$1.62 M (USD)-163.8as on Sep 30, 2025
- EBITDA$145.96 K (USD)-96.32as on Sep 30, 2025
- Latest Funding Round$840K (USD), Grant
Mar 2023
- Investors
Products & Services of Microbix
Microbix offers a comprehensive portfolio of products and services, including Antigens, External Quality Controls, DxTM Viral Transport Medium, and Custom Vial Filling Services.
Key components for developing infectious disease tests.
Products simulating patient samples for test verification.
Medium for secure specimen transport in diagnostics.
Aseptic filling for diagnostic and research applications.
Apps and channels of Microbix
its YouTube channel Microbix Biosystems Inc. has 3.12K subscribers and 21 videos.
Videos from Microbix
The most watched videos on Microbix's YouTube channel, Microbix Biosystems Inc. (3.12K subscribers). Click a video to play it here.
More on Microbix Biosystems Inc..
Funding Insights of Microbix
- Total Rounds 10
- Last Round Grant — $840,000
- First Round $88,124
(Sep 2009)
- Investors Count 1
All 10 funding rounds of Microbix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2023 | $840,000 | Grant | – | – | |
| May 2021 | $1.15M | Post-IPO | – | – | – |
| Jan 2020 | $1.78M | Post-IPO | – | – | – |
| Jun 2018 | $75,000 | Post-IPO | – | – | – |
| Feb 2014 | $1.5M | Post-IPO | – | – | – |
| Aug 2011 | $248,010 | Post-IPO | – | – | – |
| May 2011 | $239,111 | Post-IPO | – | – | – |
| Apr 2011 | $756,066 | Post-IPO | – | – | – |
| Mar 2010 | $296,283 | Post-IPO | – | – | – |
| Sep 2009 | $88,124 | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Microbix
Microbix has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ontario Canada.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Access government services and products | 1881 | ontario.ca | Toronto, Canada |
Investor details for Microbix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Microbix
22 people are tracked at Microbix (6 in leadership, 6 in board & advisors, 10 in team).
| Name | Role | Group |
|---|---|---|
Amer Alagic | Director Of Research And Development | Leadership |
Steve Hagerman | Senior Director Of Operations | Leadership |
Ken Hughes | COO | Leadership |
Jim Currie | CFO | Leadership |
Cameron L. Groome | CEO, President & Director | Leadership |
Lucy Lin | Director, QC | Leadership |
Vaughn C. Embro-Pantalony | Director | Board & advisors |
Peter M. Blecher | Director | Board & advisors |
Jennifer Stewart | Director | Board & advisors |
Mark A. Cochran | Board Member | Board & advisors |
Martin Marino | Chairman | Board & advisors |
Joe Renner | Director | Board & advisors |
Christian Sutton | Manufacturing Lab Technician | Team |
Connor Randall | R&d Technologist | Team |
Shane Niyamuddin | Senior Account Executive & Customer Service Manager | Team |
Shitika Kulshreshtha | Marketing Manager | Team |
Vibin Varghese | North American Sales & Distributor Specialist | Team |
Mark Luscher | SVP, Scientific Affairs | Team |
Mehak Thakur | Technical Writer | Team |
Phil Casselli | SVP Business Development, Sales & Marketing | Team |
2 more people are available in the full profile.
Complete people profiles for Microbix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Microbix
Microbix is a publicly listed company on the TSX with ticker symbol MBX in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Oct 1992
- Listed onTSX: MBX
- Listed entityMicrobix Biosystems Inc.
- Exchange sectorHealth technology
- ISINCA59501P1045
- Share price0.31 CAD · 2026-10-09
- Market capitalisation42,460,284.00 CAD
- EPS (diluted, trailing year)-0.04 CAD
- Volume (last session)6,400
Financials of Microbix
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 18.6M CAD | -2.2M CAD | 203,210 CAD |
| 2024 | 25.4M CAD | 3.5M CAD | 5.5M CAD |
| 2023 | 16.5M CAD | -39,480 CAD | -1.6M CAD |
| 2022 | 19.1M CAD | 1.8M CAD | 3.6M CAD |
| 2021 | 18.6M CAD | 3.2M CAD | 5.7M CAD |
Detailed financial statements for Microbix
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Microbix
4 dated milestones of Microbix across 35 years, from founding to its latest funding, stage changes and deals.
- Founded Microbix is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $88K.
- Funding Latest funding round, Grant, of $840K.
Competitors of Microbix
Microbix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. |
Detailed competitors of Microbix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Microbix
The website of Microbix (microbix.com) receives about 4.6K visits a month.
- Monthly visits4.6K
▼ 13.6% vs previous month
Websites whose visitors overlap most with Microbix. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| aristabiologicals.com | 100% | – | – | View details | |
immunospot.com | immunospot.com | 100% | – | #2,587,608 | – |
imbt.org | imbt.org | 100% | – | – | – |
| rapid123.com | 100% | – | – | View details | |
biotrend.com | biotrend.com | 100% | – | #4,074,352 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 17 similar websites and full traffic analytics for Microbix
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 17 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Microbix
Complete news archive for Microbix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Microbix
10 companies that operate in the same segment as Microbix (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Microbix
Microbix was founded in 1988 and raised its 1st funding round 21 years after it was founded.
Microbix is headquartered in Mississauga, Canada. It is registered at Mississauga, Ontario, Canada.
Annual revenue of Microbix is $13.35M as on Sep 30, 2025.
Microbix was founded in 1988 and is headquartered in Mississauga, Canada. Operations are conducted in the biotechnology sector, with expertise applied in virology and protein biochemistry. A pipeline of biological technologies has been established, including VIRUSMAX for influenza virus yield enhancement, LumiSort for semen sexing, and Kinlytic as a thrombolytic urokinase drug. Focus is placed on infectious disease antigens via cell culture, molecular biology, and related processes.
Microbix's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Microbix offers Antigens, External Quality Controls, DxTM Viral Transport Medium, and Custom Vial Filling Services.
Yes, Microbix is publicly traded on TSX under the ticker symbol MBX.
Microbix has 1 investor. Key investors include Ontario Canada.
Microbix operates through Microbix Biosystems Inc..